Transforming growth factor beta 2 mRNA (TGFB2 mRNA)

Transforming growth factor beta 2 (TGF-beta2) mRNA is the messenger RNA transcript that encodes the TGF-beta2 protein, a member of the transforming growth factor beta superfamily. This cytokine is a potent regulator of cell growth, differentiation, and immune function, but its dysregulation is a hallmark of several aggressive malignancies, including glioblastoma and pancreatic cancer (UniProt P61812). In these diseases, TGF-beta2 acts as a powerful immunosuppressant, helping tumors evade immune detection and promoting metastasis through the induction of epithelial-mesenchymal transition (PubMed: 16467104). Therapeutic strategies targeting TGF-beta2 mRNA utilize antisense oligonucleotides, such as Trabedersen (AP 12009), which bind to the mRNA sequence to prevent translation into the functional protein (PubMed: 21448170). By reducing the levels of TGF-beta2, these treatments aim to restore the host's anti-tumor immune response and inhibit tumor growth. Clinical trials have explored this target primarily in patients with high-grade gliomas, where TGF-beta2 levels correlate with disease severity and poor outcomes (PubMed: 18451147). Additionally, TGF-beta2 mRNA has been targeted in the development of cancer vaccines like Belagenpumatucel-L, which uses antisense technology to downregulate TGF-beta2 in tumor cells to enhance their immunogenicity (PubMed: 19047417).

Other names

TGF-beta2 mRNATGF-beta2 transcriptTGFB2 messenger RNATransforming growth factor beta-2 mRNA

Antisense oligonucleotide-mediated inhibition of translation, which prevents the production of the TGF-beta2 protein and subsequently reduces its immunosuppressive and pro-tumorigenic effects.